Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 2019

View Archived Issues

ALS exomes identify new culprit

Organ-specific tumor microenvironment affects response to immunotherapy

Advaxis submits IND application with the FDA for ADXS-504

Cerevance initiates phase II study of CVN-424 in Parkinson's disease

FDA clears IND application for ICTCAR-014

First patient dosed in phase II study of zilucoplan for the treatment of IMNM

Kancera presents data from in-depth analysis of KAN-D567 phase Ib program

Interim data presented from first-in-human study of AMG-596

Phase I data presented for the oncolytic virus DNX-2401 as treatment of DIPG

First-in-human data for NTM-1634 botulinum vaccine

E-Scape Bio describes new LRRK2 inhibitors

Bristol-Myers Squibb synthesizes new RORC inverse agonists

Methyltransferase-like protein 11A inhibitors identified at Purdue Research Foundation

GTx, University of Tennessee patent selective androgen receptor degraders

Incyte discloses adenosine A2A and/or A2B receptor antagonists

Immunogenomic responder phenotype for anti-LAG-3 and anti-PD-1 combination therapy

Development of preclinical canine models for pharmacological studies of AF

FDA approves IND for first-in-human study of ATRC-101 in solid tumors

Evgen enters MoU with University of Dundee to advance SFX-01 towards trial for NASH

Phase I data on SPR-720 support advancement to phase II for NTM pulmonary disease

Arecor reports phase I topline data for ultrarapid-acting insulin product candidate AT-247

Aurinia reports data from pivotal study of voclosporin in lupus nephritis

CARB-X grant supports Vedanta's VE-707 program to prevent multidrug-resistant infections

Theravance begins phase II allergen challenge study with TD-8236

NMDA receptor modulator NYX-458 begins phase II for MCI associated with Parkinson's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...